Colorectal carcinoma is the second leading cause of cancer-related deaths in the United
States, with rectal cancer accounting for approximately one-third of newly diagnosed cases …

For patients with high-risk stage II or stage III colon cancer, adjuvant chemotherapy with
fluoropyrimidine monotherapy reduces the risk of recurrence and death by approximately 20 …

Importance Although American guidelines recommend use of adjuvant chemotherapy in
patients with locally advanced rectal cancer, individuals who achieve a pathological …

Importance In March 2023, the National Comprehensive Cancer Network endorsed watch
and wait for those with complete clinical response to total neoadjuvant therapy. Neoadjuvant …

Importance Various clinical societies and patient advocacy organizations continue to
encourage minimum volume standards at hospitals that perform certain high-risk operations …

Background “Textbook oncologic outcome”(TOO) is a composite quality measure
representing the “ideal” outcome for patients undergoing cancer surgery. This study sought …

Simple Summary Immune checkpoint inhibitors (ICIs) have transformed the treatment of
mismatch repair-deficient (MMR-D)/microsatellite instability-high (MSI-H) colorectal cancers …

Background Total neoadjuvant therapy (TNT) improves tumor response in locally advanced
rectal cancer (LARC) patients compared to neoadjuvant chemoradiotherapy alone. The …

Background Locally advanced rectal cancer (LARC) typically involves neoadjuvant
chemoradiotherapy (nCRT) followed by surgery (total mesorectal excision, TME). While …

Background The trial hypothesis was that, in a resource-constrained situation, short-course
radiotherapy would improve treatment compliance compared with conventional …